Trial · NCT02162979
Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease
NCT02162979, Phase 2, Terminated, Loma Linda University; results first posted 2014-07-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease. Trials, record NCT02162979. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02162979
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease
- NCT number
- NCT02162979
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 2 participants, actual
- Lead sponsor
- Loma Linda University
- Conditions
- Parkinson's Disease
- Interventions
- sildenafil, Placebo
- First posted
- 2014-06-13
- Last updated
- 2018-03-30
- Results first posted
- 2014-07-22
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Duration of Dyskinesia. | 2 weeks | |
| Secondary | Percent Change in "on" Time | 4 weeks | "on" time is the period in which the subject is symptom free. We will track the amount of time the subject is considered symptom free before and after treatment. This value will be represented as a percent change. |
| Secondary | Change in Dose of Anti-parkinsonian Medications | 7 weeks |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Duration of Dyskinesia. | 2 weeks | |||
| SECONDARY | Percent Change in on Time | 4 weeks | |||
| SECONDARY | Change in Dose of Anti-parkinsonian Medications | 7 weeks |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Viagra | 0 | |
| Overall Study | STARTED | Placebo Comparator | 0 | |
| Overall Study | COMPLETED | Viagra | 0 | |
| Overall Study | COMPLETED | Placebo Comparator | 0 | |
| Overall Study | NOT COMPLETED | Viagra | 0 | |
| Overall Study | NOT COMPLETED | Placebo Comparator | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Viagra | ||
| Total, all-cause mortality | Placebo Comparator | ||
| Total, other adverse events | Viagra | 0 | 0 |
| Total, other adverse events | Placebo Comparator | 0 | 0 |
| Total, serious adverse events | Viagra | 0 | 0 |
| Total, serious adverse events | Placebo Comparator | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02162979
GET https://conductscience.org/api/trials/v1/NCT02162979/registered